The active ingredient, flurandrenolide, is relevant in contexts involving symptoms related to inflammatory or irritative states, including those seen in conditions such as psoriasis and eczema. Flurandrenolide is used to address the itching, redness, dryness, crusting, scaling, inflammation, and discomfort associated with various skin conditions. This formulation may be used across therapeutic domains involving chronic, symptomatic skin conditions.

---

Main Therapeutic Contexts

This medication plays a role in managing symptoms that cluster into patterns requiring supportive management, such as the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses like specific presentations of psoriasis, eczema, lichen simplex chronicus, and prurigo nodularis. It is relevant in clinical settings that involve acute or unstable symptom patterns, providing supportive relief when symptoms interfere with routine activities.

This medication helps ease the overall symptom burden by supporting the patient during difficult episodes and contributing to improved comfort, helping them cope more steadily with heightened physiological activity.

“The use of this medication supports general well-being during symptomatic phases and helps ease challenging manifestations on the skin.”

---

Quick Fact: Relief for Severe Dermatoses
This treatment supports managing intense itching (pruritus) and the visible signs of inflammation (swelling and redness) that interfere with daily functioning during flare-ups. This medication is commonly used when short-term symptomatic assistance is needed for conditions presenting with localized lesions exhibiting dryness, crusting, and severe scaling.

Regulatory References

1. NIH MedlinePlus overview

Cordran Tape (flurandrenolide tape) is a prescription topical corticosteroid indicated for the relief of inflammation and itching associated with various corticosteroid-responsive dermatoses, particularly dry, localized, and scaling skin lesions. It is designed to treat specific skin conditions as directed by a healthcare provider.

---

Who Should NOT Use Cordran Tape?

There are several situations where the use of Cordran Tape is generally advised against due to increased risks of side effects or lack of efficacy. Patients should not use this medication if they have:

• A known allergy or hypersensitivity to flurandrenolide or any component of the tape.
• Lesions that are exuding serum (oozing or weeping).
• Skin conditions in intertriginous areas (skin folds where skin rubs together, such as the armpits, groin, or between fingers/toes) due to potentially increased absorption and maceration.

Caution is also advised for individuals with existing skin infections in the treatment area, diabetes, Cushing's syndrome, or other adrenal gland disorders. Pediatric patients may be more susceptible to systemic toxicity and HPA axis suppression, requiring close monitoring and short-term use. Pregnant or breastfeeding individuals should only use the tape if the potential benefit justifies the potential risk to the fetus or infant, and extensive, long-term use is generally avoided.

Interactions with other medicines and products

Cordran Tape (flurandrenolide tape) is a topical corticosteroid, and its interaction profile is primarily related to the risk of systemic absorption of the active ingredient. Official regulatory labeling documents focus on managing this exposure.

Pharmacodynamic and Exposure Interactions

The most significant interaction consideration is the potential for additive systemic effects when Cordran Tape is used concurrently with other corticosteroid-containing preparations, including other topical steroids or systemic (oral/injectable) steroids. This combination may increase the overall risk of systemic side effects, such as HPA (hypothalamic-pituitary-adrenal) axis suppression.

Factors that augment the systemic exposure of flurandrenolide—and therefore increase the risk of potential systemic interaction—include prolonged use, application over large surface areas, and the use of additional occlusive dressings over the tape. It is officially noted that pediatric patients may absorb proportionately larger amounts of topical corticosteroids, making them more susceptible to these systemic effects.

Other Interaction Notes

Interaction Type	Official Regulatory Statement
Drug-Metabolizing Enzymes	No specific interactions with CYP enzymes or drug transporters are listed in official labeling.
Food, Alcohol, Supplements	No specific interactions with food, alcohol, or herbal products are documented.
Procedural Restriction	If a dermatologic infection is present and does not respond promptly to appropriate antimicrobial treatment, the use of Cordran Tape should be discontinued until the infection is adequately controlled.

How Cordran Tape Works

Flurandrenolide, the active ingredient, is a synthetic glucocorticoid agonist. The mechanism of action begins when flurandrenolide diffuses across cell membranes and binds to intracellular glucocorticoid receptors (GR) present in the cytoplasm of target cells.

Binding of the molecule to GR causes receptor activation and conformational changes, leading to the dissociation of chaperone proteins. The resulting steroid-receptor complex then translocates to the cell nucleus, where it acts as a transcription factor. In the nucleus, the complex engages specific DNA sequences known as glucocorticoid response elements (GREs) to modulate gene transcription.

This modulation includes both transrepression—decreasing the synthesis of pro-inflammatory proteins such as cytokines, chemokines, and inflammatory enzymes—and transactivation—increasing the synthesis of anti-inflammatory proteins, including lipocortin-1 (annexin A1). The net effect is a profound alteration of cellular signaling pathways, resulting in the decreased expression of key inflammatory mediators.

The official administration of Cordran Tape is based on its specific presentation as a medicated topical tape. The approved method is strictly topical application directly onto the skin. The dose is defined by the tape itself, which contains 4 mcg/cm^2 of flurandrenolide distributed throughout the adhesive layer.

Administration Scope

Category	Instruction
Route of administration	Topical application to the skin only.
Dosing unit	Tape cut to a size slightly larger than the lesion.
Frequency pattern	Standard replacement every 12 hours or kept in place for up to 24 hours.
Pediatric Use Principle	Administration is limited to the least amount compatible with an effective regimen.

Procedural and Contextual Constraints

Before application, the intended area of the skin must be cleaned and thoroughly dried. The application process requires careful handling, specifying that the tape must be cut from the roll, not torn, with the corners rounded off for proper fit. A specific procedural requirement exists upon removal of the tape: the skin must be cleansed and allowed to dry for 1 hour before a fresh piece of tape is applied.

Due to the tape's inherent occlusive nature, it is constrained against use on certain sites. It must not be applied to weeping lesions (lesions exuding serum) or to areas of skin folds (intertriginous areas). Furthermore, the treated area should not be wrapped or covered with any additional occlusive dressing. The overall protocol requires that treatment is discontinued when control of the condition is achieved, with re-assessment necessary if no improvement is observed within 2 weeks.

Research Evidence / Overview of Studies for Cordran Tape (Flurandrenolide Tape)

Evidence for Use in Localized, Refractory Atopic Dermatitis (Eczema)

Clinical research, often in the form of short-term Randomized Controlled Trials (RCTs), was studied for use in people with localized, chronic Atopic Dermatitis. These studies primarily focused on individuals whose thick, persistent eczema patches were considered refractory (unresponsive) to previous topical steroid treatments. The studies monitored outcomes related to physical discomfort, and also tracked specific endpoints related to skin tolerability observed during the trials. Researchers measured changes in the size and severity of the skin lesions and assessed patient-reported outcomes describing perceived discomfort, such as chronic itching.

Studies reported measurements of changes related to the thickness and hardening of the chronic skin patches (lichenification) over the short-term study period. Studies monitored data showing patterns related to severity scores measured to track the condition of the localized lesions. However, the existing evidence is limited, and long-term effects are not fully established.

Evidence for Use in Localized Neurodermatitis (Lichen Simplex Chronicus)

Cordran Tape was also evaluated in studies focusing on localized neurodermatitis, which involves patches of skin that are thickened and hardened from chronic scratching or rubbing. The research examined by conducting clinical trials and observational studies that specifically measured changes in the circumscribed, chronic plaques. The primary outcomes studies monitored included direct measurement of skin thickness and plaque size, along with tracking patient-reported outcomes describing perceived discomfort, such as the severity of chronic itching and pain associated with the lesions. What remains uncertain is the long-term data, as the existing studies provide limited information for long-term outcomes and recurrence rates.

Long-Term Studies and Follow-up Data

Research exploring short-term symptom changes has been completed, but studies focusing on extended periods are more limited. Long-term effects are not fully established, and there is limited information available that directly addresses how long any changes may persist after the drug formulation was actively applied. Consequently, certainty remains low regarding the necessity of ongoing or intermittent application, as long-term outcomes are not well characterized and data for maintenance of condition are still emerging.

Key Studies & References

1. Effect of Flurandrenolide Tape and Cream on Atopic Dermatitis

Common questions about Cordran Tape (FAQ)

---

Q: Does it make you sleepy?

Official product information, including clinical trial data, reports that dizziness and headache are common side effects. Drowsiness or feeling tired have also been reported by some patients taking this medication. Patients should be aware of these potential effects when starting treatment.

---

Q: Can you drink alcohol with this medication?

Official regulatory warnings state that using alcohol with this medication may not be recommended. This is because combining the medicine with alcohol may increase the documented risk of stomach problems, such as ulcers and internal bleeding.

---

Q: Is it safe to use during pregnancy or while breastfeeding?

Regulatory information indicates that use of this medicine should generally be avoided from about 30 weeks of pregnancy onward due to the risk of harm to the fetus. During earlier stages of the third trimester ( 20 to 30 weeks), use is advised to be limited to the lowest effective dose for the shortest period. Furthermore, due to the potential for serious adverse reactions in an infant, official regulatory documents generally recommend avoiding breastfeeding during treatment.

---

Q: What are the storage conditions for this medicine?

The official labeling specifies that the capsules should be stored at controlled room temperature, typically 25°C ( 77°F). Storage is allowed to temporarily fluctuate between 15°C to 30°C ( 59°F to 86°F). The labeling advises that the medicine be kept in a dry place.

---

Q: Can I take it for migraines?

A specific oral solution formulation of this medicine is approved by the FDA for the acute treatment of migraines with and without aura in adults. However, the regulatory label for the capsule formulation does not typically include an indication for migraine treatment.

---

Q: Is it safe long-term?

Official product information states that the medicine is typically prescribed at the lowest effective daily dose and for the shortest duration possible. This guidance is based on studies showing that the risks of serious side effects, such as cardiovascular problems, ulcers, and internal bleeding, may increase with higher doses and prolonged exposure (long-term use).

---

Q: Can children 2 years old use it?

Official FDA-approved labeling includes the treatment of Juvenile Rheumatoid Arthritis (JRA) for children 2 years of age and older. For most other approved uses, the medicine is generally not recommended for use in children under 18 years of age.

---

How to Store and Dispose of Cordran Tape?

Cordran Tape (flurandrenolide tape) must be stored and handled according to specific conditions defined in the official regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 25 C (77 F). Permitted excursions are between 15 C and 30 C.
Protection	Keep from freezing. The tape must be protected from moisture and stored away from direct light in a dry place.
Container	The product must remain in the original container (vial) and the vial must be kept tightly closed when not in use.
Safety	The medicine must be stored out of the reach of children.

Disposal Instructions

When the product is expired or no longer needed, it must be disposed of properly. Users should consult a healthcare professional for guidance on disposal. The regulatory guidance recommends using a drug take-back location or mail-back program. Cordran Tape is not on the FDA's flush list, meaning it should not be flushed down the toilet.